Pathway of Human AS3MT ArsenicMethylation

Dharmendra S. Dheeman
Herbert Wertheim College of Medicine, Florida International University, ddheeman@fiu.edu

Charles Packianathan
Herbert Wertheim College of Medicine, Florida International University, cpackian@fiu.edu

Jitesh K. Pillai
Herbert Wertheim College of Medicine, Florida International University, jpillai@fiu.edu

Barry P. Rosen
Herbert Wertheim College of Medicine, Florida International University, brosen@fiu.edu

Follow this and additional works at: https://digitalcommons.fiu.edu/all_faculty

Recommended Citation
Dheeman, Dharmendra S.; Packianathan, Charles; Pillai, Jitesh K.; and Rosen, Barry P., "Pathway of Human AS3MT ArsenicMethylation" (2010). All Faculty. 69.
https://digitalcommons.fiu.edu/all_faculty/69

This work is brought to you for free and open access by FIU Digital Commons. It has been accepted for inclusion in All Faculty by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Pathway of Human AS3MT Arsenic Methylation

Dharmendra S. Dheeman, Charles Packianathan, Jitesh K. Pillai, and Barry P. Rosen*

Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida 33199 United States

Supporting Information

ABSTRACT: A synthetic gene encoding human As(III) S-adenosylmethionine (SAM) methyltransferase (hAS3MT) was expressed, and the purified enzyme was characterized. The synthetic enzyme is considerably more active than a cDNA-expressed enzyme using endogenous reductants thioredoxin (Trx), thioredoxin reductase (TR), NADPH, and reduced glutathione (GSH). Each of the seven cysteines (the four conserved residues, Cys32, Cys61, Cys156, and Cys206, and nonconserved, Cys72, Cys85, and Cys250) was individually changed to serine. The nonconserved cysteine derivate were still active. None of the individual C32S, C61S, C156S, and C206S derivate were able to methylate As(III). However, the C32S and C61S enzymes retained the ability to methylate MAs(III). These observations suggest that Cys156 and Cys206 play a different role in catalysis than that of Cys32 and Cys61. A homology model built on the structure of a thermophilic orthologue indicates that Cys156 and Cys206 form the As(III) binding site, whereas Cys32 and Cys61 form a disulfide bond. Two observations shed light on the pathway of methylation. First, binding assays using the fluorescence of a single-tryptophan derivative indicate that As(GS)3 binds to the enzyme much faster than inorganic As(III). Second, the major product of the first round of methylation is MAs(III), not MAs(V), and remains enzyme-bound until it is methylated a second time. We propose a new pathway for hAS3MT catalysis that reconciles the hypothesis of Challenger ((1947) Sci. Prog., 35, 396–416) with the pathway proposed by Hayakawa et al. (2005) Arch. Toxicol., 79, 183–191). The products are the more toxic and more carcinogenic trivalent methylarsenicals, but arsenic undergoes oxidation and reduction as enzyme-bound intermediates.

INTRODUCTION

Arsenic is the most ubiquitous toxic substance in the environment as the result of geochemical and anthropogenic exposure. In humans, arsenic is associated with a broad range of acute and chronic toxic effects that increase the lifetime risk of cancer and diabetes as well as cardiovascular and neurological diseases. Consequently, arsenic rates first on the United States Center for Disease Control and Prevention (CDC) and Environmental Protection Agency’s (EPA) priority list of hazardous substances (http://www.atsdr.cdc.gov/spl/).

In humans, S-adenosylmethionine As(III) methyltransferase (hAS3MT, EC 2.1.1.137) catalyzes transfer of methyl groups from SAM to As(III), producing MAs, DMAs, and traces of TMAs. Human AS3MT is primarily a liver enzyme that is a member of a large superfamily of methyltransferases that are involved in many physiological functions. In humans, arsenic methylation paradoxically both detoxifies arsenic and simultaneously transforms it into carcinogenic species. Biotransformation of small molecules into carcinogens is common, and arsenic biomethylation is associated with arsenic-related cancers by conversion of inorganic arsenic (As(III)) into carcinogenic trivalent MAs(III) and DMAs(III).

To date, the pathway of methylation remains controversial. One hypothesis proposed by Challenger is that the enzyme catalyzes a series of alternating oxidative methylations and reductions, using S-adenosylmethionine as the methyl donor to generate the pentavalent products methylarsenate (MAs(V)), dimethylarsenate (DMA(V)) and a lesser amount of trimethylarsine oxide (TMAs(V)O). The trivalent species MAs(III), DMAs(III), and TMAs(III) are intermediates but not products. Most consistent with this hypothesis is that humans primarily excrete DMAs(V) and to a lesser extent MAs(V). However, with careful handling, trivalent methylated arsenicals can be detected in urine. More recently, Hayakawa and co-workers proposed an alternate pathway in which the preferred substrates of the methyltransferase are the glutathione (GSH) conjugates As(GS)3 and MAs(GS)2, and the products are the trivalent conjugates MAs(GS)3 and DMAs(GS). In this pathway, there is no change in the oxidation state of arsenic, which remains trivalent throughout the catalytic cycle. The conjugates dissociate to unstable MAs(III) and DMAs(III), which rapidly oxidize nonenzymatically in air to MAs(V) and DMAs(V), the primary observed urinary species.

Knowledge of the enzymatic mechanism of AS3MT is critical for understanding its parallel roles in arsenic detoxification and carcinogenesis. There have been few biochemical studies with purified human AS3MT. AS3MT was first purified from rat liver cytosol by Thomas and co-workers, and the rat and human genes were subsequently cloned. The enzyme methylates inorganic As(III) using SAM as methyl donor and a variety of reductants, both artificial and natural, including thioredoxin (Trx) (with an NADPH and thioredoxin reductase (TR))

Received: July 31, 2014
Published: October 17, 2014
As(III) (each at 1 μM) were quenched of intrinsic protein tryptophan derivative of hAS3MT was estimated from the synthetic enzyme. Binding of arsenicals to a single-donor thiol (2-carboxyethyl)phosphine (TCEP) supplying reducing potential. In vitro, GSH is not sufficient but increases methylation in conjunction with Trx. The identity of the physiological electron donors is not clear. Perhaps Trx and GSH have different roles in the catalytic cycle of AS3MT. This purified hAS3MT methylates As(III) primarily to DMAs(V), but, like the other hAS3MT expressed from a different clone,23 which lacks the last nine residues of the hAS3MT sequence, was chemically synthesized with 5′ Ncocl and 3′ Sall sites and with codon optimization for expression in E. coli and subcloned into the EcoRV site of pUC57-Kan (GenScript, NJ, USA). The synthetic hAS3MT gene was cloned as an NcoI/Sall digest from pUC57-Kan-hAS3MT into expression vector pET41a(+) which produces a fusion with the Schistosoma japonicum glutathione S-transferase (GST) gene at the 5′ end and eight histidine residues at the 3′ end.

To produce the natural protein, hAS3MT cDNA was generously provided by M. Styblo, University of North Carolina. The 1.1 kb fragment was amplified by PCR using forward primer 5′-CCAGCCATGCCGCTCATCTTGACGCCTGAGA-3′ (NcoI site underlined) and reverse primer 5′-CCTAGTGGACTCCAGCAGCATCGGAGACATC-3′ (Sall site underlined). The PCR product was cloned into pBAD-Myc/His-A as an NcoI/Sall digest, generating plasmid pBAD-hAS3MT in which the gene was fused with a six-histidine tag at the 3′ end. All sequences were verified by sequencing the entire gene by Sequetech, CA, USA.

Mutant Construction. Mutations in the AS3MT were introduced by site-directed mutagenesis using a QuickChange mutagenesis kit (Stratagene, La Jolla, CA). The oligonucleotides used for mutagenesis are listed in Table S1. The codons for the conserved Cys32, Cys61, Cys156, and Cys206 residues were changed to serine codons, generating seven different single-cysteine mutants of the synthetic hAS3MT. The double C32S/C61S mutant was generated by mutating codon 32 in the C61S derivative to a serine codon. Each mutation was confirmed by sequencing the entire gene.

Protein Expression and Purification. Wild-type synthetic AS3MT and its mutants were expressed in E. coli BL21(DE3). Cells bearing plasmid pET41a-hAS3MT were cultured at 37 °C in 1 L of Luria Broth medium consisting of 10 g of tryptone, 5 g of yeast extract, and 10 g of NaCl per liter containing 0.1% L-arabinose for 3 h. The natural hAS3MT was purified as described above from E. coli TOP10 (F− mcrA Δ(mrr-kdsRMS-mcrBC) q80lacZAM15 ΔlaczX74 recA1 araD1392Δ(araA-lex)7697 galU galK rpsL endA1 mupG) was employed through out.

Synthesis of the Human AS3MT Gene and Cloning of hAS3MT cDNA. A hAS3MT gene corresponding to the sequence of the cDNA clone, which lacks the last nine residues of the hAS3MT sequence, was chemically synthesized with 5′ Ncocl and 3′ Sall sites and with codon optimization for expression in E. coli and subcloned into the EcoRV site of pUC57-Kan (GenScript, NJ, USA). The synthetic hAS3MT gene was cloned as an NcoI/Sall digest from pUC57-Kan-hAS3MT into expression vector pET41a(+) which produces a fusion with the Schistosoma japonicum glutathione S-transferase (GST) gene at the 5′ end and eight histidine residues at the 3′ end.

The in vitro properties of human AS3MT have not been systematically analyzed under catalytic conditions but only in assays with stoichiometric enzyme. We also expressed a cDNA clone of human AS3MT and purified hAS3MT by heterologous expression in Esherichia coli. However, this preparation of recombinant enzyme was more active than those of other laboratories. To produce a highly active form of human AS3MT functional in catalytic concentrations and to improve expression, the hAS3MT gene was chemically synthesized with codon optimization for E. coli. Codon optimization does not alter the amino acid sequence of the protein but generally improves translation, protein folding, and activity. The synthetic enzyme exhibited high activity in catalytic concentrations. In this study, we examined the catalytic properties of the synthetic enzyme. Binding of arsenicals to a single-tryptophan derivative of hAS3MT was estimated from the quenching of intrinsic protein fluorescence, and the enzyme appears to bind As(GS)3 preferentially over inorganic As(III). In addition, MAs(III) was the primary product observed within the first few minutes of catalysis but remained mostly enzyme-bound until it was methylated a second time. These results are consistent with the pathway proposed by Hayakawa and coworkers and are inconsistent with the Challenger pathway. The involvement of the four conserved cysteine residues, Cys32, Cys61, Cys156, and Cys206, was examined by site-directed mutagenesis. Substitution of any of the four resulted in loss of ability to methylate As(III), but both the C32S and C61S derivates could still methylate MAs(III). These results suggest that only Cys156 and Cys206 are required for all steps in the methylation pathway and that Cys32 and Cys61 play a different role in the catalysis. A homology model of hAS3MT based on the crystal structure of a thermophilic orthologue indicates that Cys156 and Cys206 form the binding site for As(III) and MAs(III), whereas Cys32 and Cys61 approach each other closely enough to form a disulfide bond. We propose that this disulfide bond forms during the catalytic cycle and that a role of Trx is to reduce the disulfide and regenerate the active form of AS3MT.

| MATERIALS AND METHODS |

Reagents. Unless otherwise stated, all reagents were purchased from Sigma-Aldrich Co. LLC (St. Louis, MO). MAs(V) was reduced to MAs(III), whereas Cys32 and Cys61 approach each other forming a disulfide bond during the catalytic cycle and that a role of Trx is to reduce the disulfide and regenerate the active form of AS3MT.

Arsenic Methylation. Methylation of As(III) and MAs(III) was assayed both in E. coli expressing AS3MT genes and by purified proteins. Individual colonies of E. coli strains BL21(DE3) or TOP10

1980

bearing the appropriate plasmids were inoculated into 2 mL of Luria Broth medium supplemented with the appropriate antibiotics and incubated at 37 °C overnight. Late exponential phase cells were diluted 200-fold into 2 mL of Luria Broth medium containing 50 μg/mL kanamycin, 0.3 mM IPTG, and 20 μM sodium arsenite. After 12 h at 37 °C, the cells were removed by centrifugation, and the supernatant was immediately passed through a 3 kDa cutoff Amicon ultrafilter (Millipore, Billerica, MA). The filtrate was spiked by high-pressure liquid chromatography (HPLC) (PerkinElmer Series 2000) using a C18 reversed-phase column eluted with a mobile phase consisting of 3 mM malonic acid, 5 mM tetrabutylammonium hydroxide, and 5% (v/v) methanol (pH 7.9) with a flow rate of 1 mL/min, and arsenic content was determined by inductively coupled plasma mass spectrometry (ICP-MS) using an ELAN DRC-e spectrometer (PerkinElmer, Waltham, MA).

Methylation activity of purified AS3MTs was assayed at 37 °C in buffer B consisting of 50 mM NaH2PO4, pH 8.0, containing 0.3 M NaCl. Unless otherwise noted, the assays contained 5 mM GSH, 1 mM SAM, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH, and the reactions were terminated by adding 10% (v/v) H2O2 to oxidize all arsenic species. Denatured protein was removed by centrifugation using a 3 kDa cutoff Amicon ultrafilter. The filtrate was spiked by HPLC-ICP-MS.

Where noted, H2O2 was not added to allow for determination of trivalent arsenicals. Without oxidation, the majority of the arsenic at early times was found to be bound to the enzyme. To determine the nature of AS3MT-bound arsenicals, purified synthetic hAS3MT (5 μM) was incubated at 37 °C with 20 μM As(III) as described above for 10 min. A portion of the assay mixture was passed through a Bio-Gel P-6 column pre-equilibrated with buffer B, and then portions (25 μL) were immediately diluted with 6 M guanidine HCl or 8 M urea to denature protein and release the bound arsenicals, which were determined as described above.

Fluorescence Assays. hAS3MT has three tryptophan residues at positions 73, 203, and 213 (numbering is according to the translated cDNA sequence) (Figure S3). To obtain a single-tryptophan derivative of hAS3MT, three double-tryptophan mutants were prepared by changing two of the three tryptophan residues at each position (Table S2), creating single-tryptophan derivatives Trp73 (W203L/W213Y), Trp203 (W73R/W213Y), and Trp213 (W73R/W203Y) by site-directed mutagenesis. For removal of the GST tag, the GST−Trp73 fusion protein was incubated with thrombin (0.7 U/mg fusion protein) in a buffer consisting of 0.14 M NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and 1 mM TCEP, pH 7.3, at 23 °C for 18 h. Following the cleavage reaction, the Trp73 enzyme was purified at 4 °C using glutathione sepharose 4B (GE Healthcare, USA) following manufacturer’s instructions.

Fluorescence measurements were performed on a temperature-controlled Quantamaster UV VIS QM-4 steady state spectrophuorometer (Photon Technology International, Birmingham, NJ) at 25 °C. For steady-state measurements, both emission and excitation monochromator slits were set at 1 nm. Samples were excited at 295 nm to excite tryptophan, and emission was set at 336 nm for time-based data acquisition. Spectra were corrected for background fluorescence and Raman scattering by subtracting buffer spectra. The buffer used was 50 mM MOPS and 0.5 M NaCl, pH 7.5. For determination of relative binding of free metalloids, As(III) and MAs(III), and preformed GSH conjugates, fluorescence spectra were acquired at the indicated concentrations of arsenicals in the presence and absence of GSH. To obtain binding rates, time-based fluorescence quenching data were fitted to a single exponential decay isotherm using Prism 6 (GraphPad Software Inc.).

Homology Model of the hAS3MT Structure. A homology model of hAS3MT was built on the structure of PhAs(III)-bound CmArsM (PDB ID: 4KU9) using a fully automated protein structure homology modeling server SWISS-MODEL (http://swissmodel.expasy.org/).31 The four conserved cysteine residues (Cys32, Cys61, Cys156, and Cys206) (residue numbers are based on the hAS3MT sequence) are present in the model structure. The model quality was estimated on the basis of the QMEAN scoring function.32 The model structure with residues 44–371 (residue numbers are based on the CmArsM sequence) from PhAs(III)-bound CmArsM was used as a template, and the final homology model incorporated 308 of those 328 residues. In silico docking with SAM was carried out using the PATCHDOCK server.33 The docked hAS3MT model with SAM was superimposed with the As(III)-bound structure of CmArsM (PDB ID: 4PSD) to partly threonine atom in the As(III) binding site of hAS3MT.34 PyMOL v1.3 was used to visualize the structural models.

# RESULTS

Chemical Synthesis of hAS3MT. In two prior studies, human AS3MT was expressed from a cDNA clone and purified after heterologous expression in E. coli.20,24 In both cases, methylation was assayed using molar ratios of AS3MT/As(III) of either 1:1 or 3:1 for extended periods of time.17,24 With stoichiometric or higher ratios of enzyme to substrate, not more than a single cycle of methylation is possible, so it is not known whether each construct could attain steady state, the most commonly used approach to enzyme kinetics.35 We took a different approach to the generation of purified AS3MT that could work at catalytic rather than stoichiometric concentrations.

The sequence of the cDNA that had been used by others to produce hAS3MT was chemically synthesized. The key feature of the chemical synthesis was an increase in the codon usage bias for E. coli by upgrading the codon adaptation index from 0.64 to 0.88. In addition, the GC content was optimized, and stem-loop structures were disrupted to increase ribosome binding and the half-life of the mRNA. The stem-loop structures, which impact ribosomal binding and stability of mRNA, were broken. The final product has a total of 662 residues with 366 of the AS3MT residues unchanged from the cDNA sequence, a fusion with glutathione S-transferase at the N-terminus to improve solubility including tandem thrombin and enterokinase sites, and eight histidines at the C-terminus for purification. The changes in the synthetic sequence from that of the cDNA sequence are highlighted in Figure S1, and the sequence of the protein is shown in Figure S2.

Binding of Trivalent Arsenicals to Synthetic hAS3MT. Intrinsic tryptophan fluorescence has been extensively exploited in examining arsenic binding in arsenic detoxification proteins.28,38–41 hAS3MT has three tryptophan residues at positions 73, 203, and 213 (Figure S3). To obtain a single-tryptophan derivative of hAS3MT, three double-tryptophan mutants were prepared by changing two of the three tryptophan residues at each position (Table S2), creating single-tryptophan derivatives Trp73 (W203L/W213Y), Trp203 (W73R/W213Y), and Trp213 (W73R/W203Y) by site-directed mutagenesis. For removal of the GST tag, the GST−Trp73 fusion protein was incubated with thrombin (0.7 U/mg fusion protein) in a buffer consisting of 0.14 M NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and 1 mM TCEP, pH 7.3, at 23 °C for 18 h. Following the cleavage reaction, the Trp73 enzyme was purified at 4 °C using glutathione sepharose 4B (GE Healthcare, USA) following manufacturer’s instructions.

Fluorescence measurements were performed on a temperature-controlled Quantamaster UV VIS QM-4 steady state spectrophuorometer (Photon Technology International, Birmingham, NJ) at 25 °C. For steady-state measurements, both emission and excitation monochromator slits were set at 1 nm. Samples were excited at 295 nm to excite tryptophan, and emission was set at 336 nm for time-based data acquisition. Spectra were corrected for background fluorescence and Raman scattering by subtracting buffer spectra. The buffer used was 50 mM MOPS and 0.5 M NaCl, pH 7.5. For determination of relative binding of free metalloids, As(III) and MAs(III), and preformed GSH conjugates, fluorescence spectra were acquired at the indicated concentrations of arsenicals in the presence and absence of GSH. To obtain binding rates, time-based fluorescence quenching data were fitted to a single exponential decay isotherm using Prism 6 (GraphPad Software Inc.).

Homology Model of the hAS3MT Structure. A homology model of hAS3MT was built on the structure of PhAs(III)-bound CmArsM (PDB ID: 4KU9) using a fully automated protein structure homology modeling server SWISS-MODEL (http://swissmodel.expasy.org/).31 The four conserved cysteine residues (Cys32, Cys61, Cys156, and Cys206) (residue numbers are based on the hAS3MT sequence) are present in the model structure. The model quality was estimated on the basis of the QMEAN scoring function.32 The model structure with residues 44–371 (residue numbers are based on the CmArsM sequence) from PhAs(III)-bound CmArsM was used as a template, and the final homology model incorporated 308 of those 328 residues. In silico docking with SAM was carried out using the PATCHDOCK server.33 The docked hAS3MT model with SAM was superimposed with the As(III)-bound structure of CmArsM (PDB ID: 4PSD) to partly threonine atom in the As(III) binding site of hAS3MT.34 PyMOL v1.3 was used to visualize the structural models.
As(III) could be accelerated by addition of GSH to the buffer (Figure 1A, curve 4), which we interpret as conjugate formation in the assay buffer. When the quenching of tryptophan fluorescence was fitted to a single exponential decay isotherm, the rate with inorganic As(III) in buffer containing GSH (Figure 1A, curve 4) was approximately 130-fold faster than the rate in the absence of GSH (Figure 1A, curve 3).

Similar results were observed with addition of either MAs(III) or MAs(GS)_2. Fluorescence quenching with MAs(III) (Figure 1B, curve 3) was slow compared to that with MAs(GS)_2, but it was faster than with inorganic As(III). Fluorescence quenching could be accelerated by addition of GSH to the buffer (Figure 1B, curve 4), which was similar to quenching with preformed MAs(GS)_2 (Figure 1B, curve 5), but both were too fast to quantify. Clearly, binding of glutathione conjugates is extremely rapid, but detailed rate determinations will require stopped-flow analysis.

Catalytic Properties of Synthetic AS3MT. Initial studies investigated methylation of As(III) by hAS3MT in reaction mixtures in which physiological and nonphysiological reductants were employed. Under all conditions, As(III) was methylated to both MAs and DMAs, but the extent of methylation and the ratio of DMAs/MAs varied (Figure 2). In these assays, no differentiation was made between trivalent and pentavalent products because the reactions were terminated by addition of H2O2, which oxidizes all arsenicals to their pentavalent forms. As described below, this was necessary because a significant percentage of the total arsenic remained bound to the enzyme. Following oxidation with peroxide, all of the arsenic could be recovered. In human populations, individuals with higher conversion to DMAs have lower rates of bladder cancer and other arsenic-related diseases.42 MAs(III) is considered to be more toxic than DMAs(III), and a higher fraction of MAs excreted in urine correlates with arsenic-related diseases.16,19,42 People with more rapid methylation to DMAs may have more rapid clearance and be less susceptible to diseases. On the basis of those considerations, we define optimal hAS3MT activity as conditions that resulted (1) in the greatest total methylation and (2) produced the highest ratio of DMAs to MAs. Under the conditions employed, hAS3MT showed the highest activity with the combination of cysteine and the artificial reductant TCEP. Note that nearly all of the As(III) was methylated with an As(III)/hAS3MT ratio of 10, the first example of multiple rounds of catalysis by purified hAS3MT. With possible physiological reductants, GSH alone produced the lowest activity. High activity was observed with addition of purified Trx plus a Trx-regenerating system consisting of NAPH and TR (termed the Trx system). With the Trx system, the DMAs/MAs ratio was similar to that with TCEP alone (5.5−7.3). Addition of GSH to either TCEP or
the Trx system both increased total methylation and the DMAs/MAs ratio (7.0–11.7). Thus, GSH is not a particularly good reductant but might play a different role than Trx, such as forming the As(GS)₃ substrate.²

Precursor–Product Relationship of hAS3MT Methyl-ation. The time course of As(III) methylation over a 3 h period was determined using GSH and the Trx system (Figure 3A). The production of MAs was linear over the first 10 min, reaching a plateau at 30 min and decreasing to nearly zero after 180 min. At this point, MAs accounted for approximately about 15% of the total arsenic in the reaction mixture. The production of DMAs had a lag of approximately 10 min and then increased until 97% of the total arsenic was present as DMAs. These results are consistent with the Briggs–Haldane steady-state assumption of enzyme catalysis, which predicts a precursor–product relationship for an irreversible reaction.³⁷ In this case, the immediate product is MAs, which disappears as it is converted to the major product DMAs. Under similar conditions, the native enzyme from the cDNA construct exhibited little methylation activity (Figure 3B). When both synthetic and native enzyme were present at catalytic concentrations (1 μM enzyme and 10 μM As(III)), little DMAs was produced by the native enzyme after 2 h, compared with 80% conversion with the synthetic enzyme. Thus, the synthetic enzyme is active when present in catalytic concentrations, whereas the purified native enzyme is not. Although we cannot eliminate other possibilities, a logical inference is that they differ in conformation, perhaps because the native enzyme does not fold as well as the synthetic enzyme, which was optimized for E. coli expression. One possible explanation is that the native gene has a total of 17 rare codons for Arg, Leu, Ile, and Pro that were corrected in the synthetic gene. That could slow the rate of translation and hence the rate of folding of the native protein.

Figure 3. As(III) methylation by synthetic and native hAS3MTs. The reaction mixture (1.5 mL) containing 1 μM of either purified synthetic (A) or native (B) hAS3MT, 1 mM SAM, 5 mM GSH, 10 μM Trx, 3 μM TR, 0.3 mM NADPH, and 10 μM As(III) was incubated at 37 °C. Samples were withdrawn at the indicated times, and the reaction terminated by addition of 10% (v/v) H₂O₂, final concentration, and analyzed by HPLC-ICP-MS. The data are the mean ± SE (n = 3).

Figure 4. MAs(III) forms an enzyme-bound intermediate. (A) Formation of soluble MAs(III). Purified hAS3MT (1 μM) was incubated at 37 °C with 10 μM As(III) containing 5 mM cysteine and 1 mM SAM for the indicated times. Protein was removed, and the soluble arsenicals were speciated by HPLC-ICP-MS. (B) Formation of enzyme-bound MAs(III). Purified hAS3MT (5 μM) was incubated at 37 °C with 20 μM As(III) containing 5 mM GSH, 1 mM SAM, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH. After 10 min, samples were separated through a Bio-Gel P-6 spin column. Portions (25 μL) were diluted with 6 M guanidine HCl or 8 M urea to final concentrations of 4 M to denature the protein and release the enzyme-bound arsenicals, which were analyzed by HPLC-ICP-MS.
Figure 4. Role of cysteine residues in methylation of As(III). (A) In vivo methylation of As(III) by wild-type and mutant hAS3MTs. E. coli BL21 (DE3) cells bearing vector pET41a(+) or plasmids with wild-type or cysteine mutant genes in pET41a-hAS3MT were grown in 2 mL of Luria Broth medium in the presence of 20 μM As(III), 0.3 mM IPTG, and 50 μg/mL kanamycin at 37 °C for 12 h. (B) Methylation of As(III) by purified wild-type and mutant hAS3MTs. Methylation of As(III) was assayed at 37 °C after 3 h with 10 μM As(III), 1 μM hAS3MT, 1 mM SAM, 5 mM GSH, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH.

The Initial Product of the Methylation Reaction Is Trivalent and Remains Bound to the Enzyme. After 10 min at 37 °C, synthetic hAS3MT methylated As(III) to soluble MAs(V), with little MAs(V) observed (Figure 4A). These results support the postulate of Hayakawa et al. that the products of hAS3MT are trivalent, not pentavalent.6 However, at early times the majority of the arsenic appeared to be insoluble, and we predicted that it is bound to the enzyme. To examine this possibility, As(III) methylation was carried out for 10 min with concentrations of enzyme (5 μM) and As(III) (20 μM) higher than in the usual assay conditions to obtain sufficient enzyme-bound form. Unbound arsenic was removed, and the protein with bound arsenicals was denatured with guanidine HCl or urea to release the protein-bound arsenicals (Figure 4B). When a protein is denatured with guanidine HCl or urea, it is unfolded, disrupting the secondary and tertiary structures. Because substrate binding sites in enzymes are composed of amino acid residues that are brought together in precise distances and geometries, unfolding of the protein will destroy the binding site and release noncovalently bound ligands. Denatured protein was removed by filtration, and the filtrate was speciated by HPLC-ICP-MS. MAs(V) was the acceptable range.32 The homology model incorporated 308 elements.

A homology model of hAS3MT was nearly the same as that of the CmArsM structure, with equivalent metalloid and SAM binding elements. In silico docking with SAM was carried out using the program PATCHDOCK.33 This model was superimposed with the As(III)-bound structure of CmArsM (PDB ID: 4KU9) using the SWISS-MODEL fully automated protein structure homology modeling server (http://swissmodel.expasy.org/) (Figure 7).31 The model quality was estimated on the basis of a qualitative model energy analysis scoring function of 0.64, which is within the acceptable range.32 The homology model incorporated 308 of 328 residues from 4KU9. The secondary structural arrangement of hAS3MT was nearly the same as that of the CmArsM structure, with equivalent metalloid and SAM binding elements. In silico docking with SAM was carried out using the program PATCHDOCK.33 This model was superimposed with the As(III)-bound structure of CmArsM (PDB ID: 4FSD) to place an arsenic atom in the As(III) binding site of hAS3MT, suggesting a more subtle role in the

Effect of Substitution of Conserved Cysteine Residues on hAS3MT Activity. As(III) SAM methyltransferases have four conserved cysteine residues (Figure S3), Cys32, Cys61, Cys156, and Cys206, in hAS3MT.28,43 The CDNA clone lacks the last nine residues of the actual hAS3MT sequence, including three cysteine residues, but there are seven other nonconserved cysteines (Cys72, Cys85 Cys226, Cys250, Cys271, Cys334, and Cys360). Of these nonconserved residues, Cys72, Cys85, and Cys250 were altered to serine residues, and cells expressing the C72S, C85S, and C250S derivatives retained the ability to methylate As(III) (Figure 5A). When the conserved cysteines were altered to serine residues, and cells expressing the C32S, C61S, C156S, and C206S derivatives did not methylate As(III) (Figure 5A). The C32S, C61S, C156S, C206S, and C32S/C61S derivatives were expressed, and the activity of the purified enzymes examined. None of the altered proteins was able to methylate inorganic As(III) even after 3 h (Figure 5B). In contrast, C32S and C61S retained the ability to methylate MAs(V) (Figure 6), whereas neither C156S nor C206S were able to do so (data not shown). Although the results of mutagenesis are always open to interpretation, these observations indicate that Cys156 and Cys206 are essential for both the first and second cycles of methylation, whereas Cys32 and Cys61 are required for the first methylation but not the second. Thus, there appears to be two classes of cysteine residues: Cys32 and Cys61 in one class and Cys156 and Cys206 in the other.
catalytic cycle. In the model, Cys156 and Cys206 form an As(III) binding site, with the arsenic atom 2.2 and 2.3 Å from the sulfur atoms of Cys156 and Cys206, respectively. In contrast, Cys32 and Cys61 are oxidized in a disulfide bond. The methyl group of SAM was oriented toward the bound As(III) at approximately 3.9 Å distance.

A Disulfide Bond Cascade Reaction Mechanism for hAS3MT. On the basis of a combination of experimental data and structural modeling, we propose a novel reaction scheme involving a disulfide bond cascade with at least two sequential disulfide bonds: the first between Cys32−Cys61 and the second between Cys61−Cys156 (Figure 8), based on the disulfide bonds observed in the crystal structures of the Cyanidioschyzon merolae orthologue (PDB IDs: 4KU9 and 4FR0). The catalytic cycle for the first two rounds of methylation can be summarized in eight steps. (1) In the first round of methylation, hAS3MT binds As(III) in a series of three thiol transfer reactions from As(GS)₃, which is the preferred substrate (Figure 1). (2) The methyl group of SAM is attacked by the arsenic lone pair, (3) which leads to formation of a transient positively charged pentavalent MAs(V) intermediate. 44 (4) The role of Cys32 (or Cys61; at this time, we cannot distinguish between them) is to provide electrons to reduce enzyme bound MAs(V) to MAs(III) and to allow the next round of methylation. By donating electrons to the arsenic, Cys32 (or Cys61) becomes oxidized, forming a disulfide bond with Cys61. (5) The role of Trx is to reduce the disulfide bond, consistent with the traditional role of thioredoxins in facilitating reduction of protein cysteine disulfides by thiol−disulfide exchange. Oxidized Trx is reduced by TR with electrons from NADPH. MAs(III) remains strongly bound by the thiol pair Cys61−Cys156. The disulfide bond is reduced with Trx, and (6) the enzyme undergoes the next round of methylation, forming a transient positively charged pentavalent DMAs(V) intermediate, (7) which is reduced to DMAs(III) by Cys61, forming a Cys61−Cys156 disulfide. (8) The disulfide is reduced by Trx, regenerating the enzyme and releasing the major soluble product, DMAs(III). Finally, in

Figure 6. Role of cysteine residues in methylation of MAs(III). Methylation of MAs(III) by cysteine mutants was assayed at the indicated times at 37 °C with 10 μM MAs(III), 1 μM hAS3MT, 1 mM SAM, 5 mM GSH, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH. The reaction was terminated by addition of 10% (v/v) H₂O₂, final concentration. Protein was removed before analysis, and soluble arsenicals were analyzed by reversed-phase HPLC-ICP-MS. (A) Synthetic wild-type hAS3MT. (B) C32S mutant. (C) C61S mutant. (D) C32S/C61S double mutant. The C156S and C206S derivatives did not methylate MAs(III) (not shown).
urine, exposure to air nonenzymatically oxidizes DMAs(III) to DMAs(V). Thus, the substrates and products are all trivalent, as predicted by Hayakawa et al., but the arsenic undergoes a cycle of oxidation and reduction, as hypothesized by Challenger, but only when it is enzyme-bound. GSH and Trx are involved, but not as reductants of pentavalent intermediates. Instead, As(GS)_3 serves as the arsenic donor to the enzyme, as hypothesized by Hayakawa et al., and Trx is a protein disulfide reductase. Advantages of this pathway are that it explains current results with As(III) SAM methyltransferases and reconciles the proposals of Challenger and Hayakawa et al.

**DISCUSSION**

Arsenic is clearly a health hazard, but is it inorganic or methylated arsenicals that produce the risk? The answer depends in large part on the products of AS3MT, the enzyme...
that methylates arsenic in liver and other organisms. There are two schools of thought on this matter. The original proposal by Challenger in the 1940s involved a series of oxidative methyllations such that the substrates were trivalent arsenicals and the products were pentavalent.\(^1\) A more recent proposal by Hayakawa et al. suggests that both the substrates and products are trivalent, a key difference between the two major proposals.\(^2\) If Challenger is correct, then the products are relatively nontoxic and noncarcinogenic. If Hayakawa et al. is correct, then the products are more toxic and carcinogenic than the inorganic As(III) substrate.

Challenger was ahead of his time since nothing was known of the very large superfamily of methyltransferase enzymes in the 1940s. Members of that superfamily append a methyl group from SAM to acceptor groups by \(S_N2\) displacement mechanisms, involving attack of a nucleophile on the methyl group of SAM with inversion of configuration and concomitant release of SAH.\(^11\) Methyltransferases are categorized on the basis of the electron-rich, methyl-accepting atom, usually O, N, C, or S. These enzymes have been studied in exquisite detail for more than 50 years. They all have a conserved SAM binding fold and use a common enzymatic mechanism of methyl-transfer, where SAM serves as a potent alkylating agent with destabilization of the sulfonium ion. While Challenger proposed a series of oxidations and reductions along with three rounds of methylation, none of the \(O\)-, \(N\)-, \(C\)- and \(S\)-methyltransferases oxidizes their substrates, and no one has demonstrated the presence of a pentavalent arsenic intermediate bound to AS3MT or its orthologues. The evidence that AS3MT directly generates As(V) metabolites is not strong. Lysine and arginine methyltransferases are good models for arsenic methyltransferases, as they carry out three very similar methyl transfers without oxidation of the nitrogen. In summary, methyltransferases methylate their substrates without oxidation. Nature is conservative, and there is no reason to consider that AS3MT would use a different enzymatic mechanism from that of any other member of the superfamily.

Yet, a major chemical difference between the metalloid arsenic and the nonmetal atoms (O, N, C, S) acceptors of the methyl group is its redox activity. For that reason, there is the possibility that As(III) in the metalloid binding site of hAS3MT becomes oxidized during the catalytic cycle and is reduced again by donation of electrons from the conserved cysteine residues. Thus, we propose the formation of the transient pentavalent intermediates shown in steps 3 and 6 of our proposed reaction cycle (Figure 8). However, it is not clear if pentavalent intermediates are obligatory components in the mechanism or side reactions that are the consequences of oxidation. Regardless of whether AS3MT catalyzes alternation between reduced substrates and oxidized intermediates, transient trivalent intermediates are likely to be easily oxidized, and there must be a mechanism to keep them reduced. In either case, the disulfide bond cascade that takes place using the conserved cysteine residues of AS3MT is a novel feature of As(III) SAM methyltransferases that differentiates it from other members of the methyltransferase superfamily.

Another prediction of Hayakawa et al. is that the substrate is As(GS)\(_3\), and not free inorganic arsenic. This is very reasonable because GSH, the major thiol in cells, is present at millimolar concentrations and reacts readily with As(III) to form the triglutathione complex inside cells.\(^46\) Some microorganisms use thiols other than GSH as their major intracellular reductant.\(^47\) Although we have no data on methylation in any of those organisms, we can predict that they will be able to use other As—thiol conjugates. Dithiols can readily abstract As(III) from As(GS)\(_3\), so it is also reasonable that As(GS)\(_3\) is able to donate As(III) to conserved cysteine residues in hAS3MT.\(^48\) The As(GS)\(_3\) complex is unstable in vitro, so it is challenging to observe its interaction with enzymes. Quenching of intrinsic protein fluorescence by arsenicals in single-tryptophan derivatives has been shown to reflect binding.\(^55,41\) Using single-tryptophan derivatives, we examined the transfer of As(III) from As(GS)\(_3\) to the binding site in the ArsD metallochaperone and the CmArsM orthologue of hAS3MT. We took a similar approach with hAS3MT by introduction of a single tryptophan, Trp73, adjacent to the predicted As(III) binding site. The results are striking: free inorganic As(III) binds over a period of minutes, whereas preformed As(GS)\(_3\) binds in seconds. Similarly, MAs(GS)\(_2\) bound faster than MAs(III). An enzyme that takes minutes to bind its substrate is not a very useful catalyst. If As(III) was added to GSH-containing buffer, quenching was enhanced relative to that with GSH-free buffer, indicating formation of the conjugates during the course of the assay. Even As(GS)\(_3\) quenched fluorescence faster when the buffer contained GSH, suggesting that the conjugate dissociates when diluted into GSH-free buffer but is stabilized when the buffer contains GSH. These results are most consistent with the glutathione conjugates of inorganic and methylated arsenicals serving as the source of arsenic for hAS3MT.

### ASSOCIATED CONTENT

#### Supporting information

Oligonucleotide primers for mutagenesis of cysteine and tryptophan residues, nucleotide sequence of the hAS3MT cDNA clone and the synthetic gene, amino acid sequence of synthetic hAS3MT, and multiple alignment of hAS3MT with orthologues. This material is available free of charge via the Internet at http://pubs.acs.org.

### AUTHOR INFORMATION

**Corresponding Author**

E-mail: brosen@fiu.edu.

**Funding**

This work was supported by National Institutes of Health grant R37 GM55425.

**Notes**

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

We thank Joris Messens for the gift of plasmids and to Miroslav Stylbo for the cDNA clone and for discussions on the nature of the bound intermediate.

### ABBREVIATIONS

AS3MT, As(III) S-adenosylmethionine methyltransferase; MAs(III), dimethylarsenite; MAs(V), dimethylarsenate; MAs(III), trimethylarsenite; TMAs(III), trimethylarsine oxide; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; TCEP, tris(2-carboxyethyl)phosphine hydrochloride; GuHCl, guanidine hydrochloride; GSH, reduced glutathione; As(GS)\(_3\), arsenic triglutathione; TR, thioredoxin reductase; Trx, thioredoxin; IPTG, isopropyl \(\beta\)-D-1-thiogalactopyranoside.
Chemical Research in Toxicology

REFERENCES


